Skip to content
Teethgrinder – Lifestyle
Author:
Io Therapeutics, Inc.
RXR Nuclear Receptor Agonists Promote Clearance of Alpha-Synuclein in Cellular Models
August 5, 2026
Io Therapeutics, Inc. announces publication of studies on the company’s RXR agonist compound IRX4204 for breast cancer prevention
March 11, 2026